Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why ImmunoGen Fell Today

By Brian Orelli, PhD - Oct 22, 2018 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data presented at a medical conference weren't as good as investors were hoping for.

What happened

Shares of ImmunoGen ( IMGN 9.72% ) are down 14.9% at 11:34 a.m. EDT after the biotech reported data from the Forward II trial testing its drug mirvetuximab soravtansine, combined with Merck's ( MRK -0.63% ) Keytruda, in ovarian cancer patients. Unfortunately, the data, which was presented at the European Society for Medical Oncology (ESMO) 2018 Congress, didn't look nearly as good as the findings for the initial 14 patients that were presented previously.

Merck was trading flat on the day. The big pharma certainly isn't counting on this combination to drive sales of Keytruda. And Merck had multiple presentations of its own at ESMO that are more likely to set its valuation.

Doctor talking to a female patient in front of a window.

Image source: Getty Images.

So what

Most patients, 45 of 54, or 83%, to be exact, saw their tumors shrink, but most of those didn't reach the level to be considered responders. All told, there were 16 confirmed partial responses, for a confirmed overall response rate (ORR) of just 30%. Previously, in the initial 14 patients, the ORR was 43%.

Looking at the patients with medium or high FRalpha expression -- the target of mirvetuximab -- the confirmed ORR was 31%, down substantially from the 63% ORR seen in the initial eight patients.

It should be noted that these are still initial data, so there are some unconfirmed responses that could turn into confirmed responses. And a response rate of 30% is higher than some have seen with ovarian cancer patients who have failed multiple previous treatments. While it's hard to compare across trials, the patients in ImmunoGen's trial had previously received a median of three therapies.

But this is still a prime example of why investors should always be cautious of interpreting interim data from small populations. Depending on who was enrolled initially, the results could be off substantially from the true response rate.

Now what

The lower response rate is certainly bad news for the potential long-term sales of mirvetuximab but probably doesn't say much about its short-term prospects, which are tied to Forward I, a phase III study testing mirvetuximab as a monotherapy, which is scheduled to read out next year.

Investors who can't wait that long will get some data for a pair of ImmunoGen's phase I blood cancer drugs, IMGN779 and IMGN632, at the American Society of Hematology meeting in December.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$6.77 (9.72%) $0.60
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$74.44 (-0.63%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.